FI965032A0 - Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita - Google Patents

Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita

Info

Publication number
FI965032A0
FI965032A0 FI965032A FI965032A FI965032A0 FI 965032 A0 FI965032 A0 FI 965032A0 FI 965032 A FI965032 A FI 965032A FI 965032 A FI965032 A FI 965032A FI 965032 A0 FI965032 A0 FI 965032A0
Authority
FI
Finland
Prior art keywords
interleukin
specific antibodies
heavy
light chain
effective anti
Prior art date
Application number
FI965032A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI965032A (fi
Inventor
John Spencer Emtage
Mark William Bodmer
Diljeet Singh Anthwal
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Publication of FI965032A publication Critical patent/FI965032A/fi
Publication of FI965032A0 publication Critical patent/FI965032A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI965032A 1994-06-17 1996-12-16 Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita FI965032A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9412230A GB9412230D0 (en) 1994-06-17 1994-06-17 Interleukin-5 specific recombiant antibodies
PCT/GB1995/001411 WO1995035375A1 (en) 1994-06-17 1995-06-16 Interleukin-5 specific recombinant antibodies

Publications (2)

Publication Number Publication Date
FI965032A FI965032A (fi) 1996-12-16
FI965032A0 true FI965032A0 (fi) 1996-12-16

Family

ID=10756925

Family Applications (1)

Application Number Title Priority Date Filing Date
FI965032A FI965032A0 (fi) 1994-06-17 1996-12-16 Interleukiini-5-spesifisiä yhdistelmä-vasta-aineita

Country Status (18)

Country Link
US (3) US5998586A (no)
EP (1) EP0765392B1 (no)
JP (1) JP3973682B2 (no)
AT (1) ATE264389T1 (no)
AU (1) AU694783B2 (no)
CA (1) CA2192543C (no)
CZ (1) CZ292295B6 (no)
DE (1) DE69532889T2 (no)
ES (1) ES2218546T3 (no)
FI (1) FI965032A0 (no)
GB (1) GB9412230D0 (no)
HU (1) HU221641B1 (no)
IL (1) IL114179A (no)
NO (1) NO964808L (no)
NZ (1) NZ287927A (no)
SK (1) SK282625B6 (no)
WO (1) WO1995035375A1 (no)
ZA (1) ZA954990B (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
CN100391977C (zh) * 1994-12-23 2008-06-04 史密丝克莱恩比彻姆公司 用于治疗il-5介导的疾病的重组il-5拮抗剂
AU777952B2 (en) * 1999-04-23 2004-11-04 Pharmexa A/S Method for down-regulating IL5 activity
ES2514495T3 (es) 2006-05-25 2014-10-28 Glaxo Group Limited Anticuerpos humanizados modificados anti-interleucina-18
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
EP2337801A4 (en) * 2008-10-06 2012-07-25 Minerva Biotechnologies Corp MUC1 ANTIBODIES *
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HUE058896T2 (hu) 2010-10-01 2022-09-28 Modernatx Inc N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
PT2654790T (pt) * 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP4074834A1 (en) 2012-11-26 2022-10-19 ModernaTX, Inc. Terminally modified rna
EP3530284B1 (en) 2012-12-26 2023-10-25 OncoSynergy, Inc. Anti-integrin beta1 antibody compositions and methods of use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
MX2016004249A (es) 2013-10-03 2016-11-08 Moderna Therapeutics Inc Polinulcleotidos que codifican el receptor de lipoproteina de baja densidad.
WO2016004045A1 (en) * 2014-06-30 2016-01-07 Academia Sinica Antagonists for interleukin-17 receptor b (il-17rb) and its ligand il-17b for cancer therapy
CA2976089A1 (en) 2015-02-10 2016-08-18 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
JP7295038B2 (ja) 2017-06-06 2023-06-20 グラクソスミスクライン エルエルシー 小児患者のための生物薬剤組成物及び方法
MX2020003034A (es) 2017-09-29 2020-07-22 Jiangsu Hengrui Medicine Co Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
US20220010008A1 (en) * 2018-12-12 2022-01-13 Shanghai Pharmaexplorer Co., Ltd. Anti-human interleukin 5(il-5) monoclonal antibody and use thereof
AU2020251627A1 (en) 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0441891A1 (en) * 1988-11-03 1991-08-21 Schering Corporation Method of preventing or reducing eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
CA2129445A1 (en) * 1992-02-06 1993-08-07 Chuan-Chu Chou Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
EP0627002B1 (en) * 1992-02-19 1998-09-23 Schering Corporation Cloning and expression of humanized monoclonal antibodies against human interleukin-4
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies

Also Published As

Publication number Publication date
AU694783B2 (en) 1998-07-30
IL114179A (en) 2001-08-26
ES2218546T3 (es) 2004-11-16
US20020042089A1 (en) 2002-04-11
JPH10501697A (ja) 1998-02-17
DE69532889D1 (de) 2004-05-19
FI965032A (fi) 1996-12-16
SK282625B6 (sk) 2002-10-08
GB9412230D0 (en) 1994-08-10
NZ287927A (en) 1998-07-28
NO964808L (no) 1997-02-17
JP3973682B2 (ja) 2007-09-12
CA2192543C (en) 2008-07-29
CA2192543A1 (en) 1995-12-28
CZ292295B6 (cs) 2003-08-13
HU221641B1 (hu) 2002-12-28
HUT76672A (en) 1997-10-28
EP0765392B1 (en) 2004-04-14
HU9603183D0 (en) 1997-01-28
ATE264389T1 (de) 2004-04-15
DE69532889T2 (de) 2005-03-10
US6734286B2 (en) 2004-05-11
WO1995035375A1 (en) 1995-12-28
AU2680395A (en) 1996-01-15
US5998586A (en) 1999-12-07
CZ371296A3 (cs) 1998-05-13
SK160096A3 (en) 1997-06-04
US6316227B1 (en) 2001-11-13
IL114179A0 (en) 1995-10-31
ZA954990B (en) 1996-12-17
EP0765392A1 (en) 1997-04-02
NO964808D0 (no) 1996-11-13

Similar Documents

Publication Publication Date Title
DE69532889D1 (de) Interleukin-5-spezifische rekombinante antikörper
FI956112A (fi) Monoklonaalinen anti- V-integriinivasta-aine
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DK0812333T3 (da) Bispecifikt antistof, som er effektivt til behandling af B-cellelymfom og cellelinie
PT778891E (pt) Anticorpo monoclonal recombinante anti-rhesus d (d7c2)
DE68914244D1 (de) Monoklonaler Antikörper.
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
TR199800517A3 (tr) Hümanize anti-hümen fas antikor.
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
NO890116D0 (no) Monoklonale antistoffer.
DE69023717D1 (de) Monoklonaler Antikörper.
DE69020315D1 (de) Monoklonaler antikörper gegen c-reaktives protein.
ITRM920223A0 (it) Anticorpi monoclonali anti-idiopici diretti contro anticorpi anti-tnf.
DE69427850D1 (de) Monoklonaler antikörper gegen mucoglykoprotein
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
BR1100555B1 (pt) anticorpos monoclonais humanizados.
DE69324928D1 (de) Monoklonaler antikörper
FI960566A0 (fi) Monoklonaalinen vasta-aine, joka tunnistaa välisolun pinta-antigeenin
DE68916088D1 (de) Anti-CPBII-monoklonaler Antikörper.
DE69320192D1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
DK0778891T3 (da) Rekombinant monoklonalt antistof mod rhesus D (D7C2)

Legal Events

Date Code Title Description
FD Application lapsed

Free format text: ABB OY